

SMS Lifesciences India Limited

Registered & Corporate Office:

Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School,

Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA. Tel: +91-040-6628 8888, Fax: +91-40-2355 1401

CIN: L74930TG2006PLC050223

Email: info@smslife.in, Website: www.smslife.in

August 19, 2020

To

BSE Limited,

Listing Department, P J Towers,

Dalal Street.

Mumbai - 400001.

Scrip code: 540679

Through: BSE Listing Center

Dear Sir/Madam,

National Stock Exchange of India limited,

Listing Department, "Exchange Plaza",

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NEAPS

SUB: UPDATE ON RANITIDINE HCL.

Ref: Our communication dated (i) 17.09.2019 (ii) 30.09.2019 (iii) 10.10.2019 (iv) 04.11.2019 and (v) 09.04.2020 read with USFDA News release dated April 1, 2020

In-furtherance to aforementioned communications, we would like to update that post USFDA statement to recall and review the said molecule, various Regulatory Authorities *globally* are reviewing the information and few have halted the procurement; customers in some countries are taking trial with improved processes and will decide further course of action.

Company is currently providing the molecule within prescribed NDMA impurity Limits at release and is constantly working on quality improvement. Even though some production and supply is going on but there will be reduction in sales contribution of Ranitidine for the financial year 2020-21.

Financial Impact: Ranitidine being a high volume and low margin business; coupled with some good sales figures of other existing products; we do not foresee any significant impact on the profitability and we are confident of maintaining a sustainable revenue stream.

ences In

Hyderabad

This is for your information and records.

Thanking You,

For SMS Lifesciences India Limited

Trupti Ranjan Mohanty
Company Secretary